According to GlobalData’s medical device pipeline database, 45 Disease Specific Test Reagents devices are in various stages of development globally. GlobalData’s report Disease Specific Test Reagents provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, nine are in active development, while the remaining 36 are in an inactive stage of development. There are seven products in the early stages of development, and the remaining two are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Disease-specific test reagents are chemicals or biological substances that are used to detect the presence of a particular disease or condition in a patient’s blood or other bodily fluids. These reagents are used in a variety of diagnostic tests, including blood tests, urine tests, and tissue biopsies. Some common examples of disease-specific test reagents include: Enzyme-linked immunosorbent assays (ELISA), Immunochromatographic assays (IC) and Polymerase chain reaction (PCR).
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Disease Specific Test Reagents pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Disease Specific Test Reagents devices. Overall, most of these Disease Specific Test Reagents pipeline devices are being developed by private entities.
Key players involved in the active development of Disease Specific Test Reagents include Grifols, DiaSorin, Coland, ELITechGroup, OncoHealth, Sekisui Medical, University of Washington, Suzhou Boi Biology, Sysmex and Tauns Laboratories.
For a complete picture of the developmental pipeline for Disease Specific Test Reagents devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
